Data access committee handling data access requests for biomarker data from the clinical trial IMmotion150.

Request Access

Dataset ID	Description	Technology	Samples
EGAD00001004183	Tumor transcriptome and whole exome sequencing data (matched tumor/normal for somatic mutation calling) along with key phenotypic information are provided for patients enrolled in the phase 2 IMmotion150 trial, assessing efficacy of atezolizumab monotherapy or combination of atezolizumab and bevacizumab versus standard of care (sunitinib) in 1L renal cell carcinoma. This data set accompanies the respective Nature Medicine publication (PMID: 29867230).	Illumina HiSeq 2500	589